3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Carcinoma, Hepatocellular
3
Neoplasms
2
Breast Neoplasms
2
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Ototoxicity
1
Heart Failure
1
Endometrial Neoplasms
1
Endometrial Hyperplasia
1
Cardiovascular Diseases
1
Cardiotoxicity
1
Atherosclerosis
1
Interventions
Echocardiography
14
Doxorubicin
10
Exercise
8
Electrocardiography
7
Trastuzumab
6
Cyclophosphamide
5
Carvedilol
5
Docetaxel
3
Atorvastatin
3
salicylhydroxamic acid
2
sacubitril and valsartan sodium hydrate drug combination
2
empagliflozin
2
dapagliflozin
2
Tablets
2
Social Determinants of Health
2
Silymarin
2
Magnetic Resonance Spectroscopy
2
Ivabradine
2
High-Intensity Interval Training
2
Exercise Test
2
Chemoradiotherapy
2
Blood Specimen Collection
2
Bisoprolol
2
Antineoplastic Agents
2
Anthracyclines
2
sulforaphane
1
schizandrin
1
pegfilgrastim
1
nicotinamide-beta-riboside
1
mitoquinone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Cardiotoxicity
×
Hydroxymethylglutaryl-CoA Reductase Inhibitors
×
Clear all
NCT03186404
2022-02-08
SPARE-HF
University Health Network, Toronto
Phase 2
Unknown
112 enrolled